Logo with tm.png
Alector Presents Results from First-in-Human Phase 1 Study of AL101 for the Treatment of Neurodegenerative Diseases
November 29, 2022 11:05 ET | Alector, Inc.
AL101 is being developed to elevate progranulin (PGRN) levels with dosing regimens to be optimized for larger indications such as Alzheimer’s disease Study results in healthy volunteers demonstrated...
Logo with tm.png
Alector Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 16:05 ET | Alector, Inc.
Progressing enrollment in the INFRONT-3 Phase 3 pivotal study for latozinemab (AL001) and in the INVOKE-2 Phase 2 study for AL002 Initiated first-in-human Phase 1 trial of AL044, the company’s third...
Logo with tm.png
Alector to Participate in Upcoming Healthcare Conferences
November 07, 2022 07:00 ET | Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Logo with tm.png
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
November 03, 2022 16:30 ET | Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Logo with tm.png
Alector Announces Promotion of Clare Hunt to Chief People Officer
October 13, 2022 08:00 ET | Alector, Inc.
Promotion demonstrates Alector’s commitment to building a world-class culture that questions convention, embraces feedback and promotes development for all employees Company recently earned...
Logo with tm.png
Alector Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
October 06, 2022 16:30 ET | Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology and innate immuno-oncology, today...
Logo with tm.png
Alector Initiates Phase 1 Clinical Trial of AL044 for the Treatment of Alzheimer’s Disease (AD)
September 12, 2022 07:00 ET | Alector, Inc.
AL044 is the first clinical-stage drug candidate targeting MS4A, a major genetic risk factor for AD AL044, a novel first-in-class therapeutic candidate, seeks to counteract multiple AD pathologies...
Logo with tm.png
Alector to Participate in Upcoming Healthcare Conferences
September 07, 2022 07:00 ET | Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Logo with tm.png
Alector Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022 16:05 ET | Alector, Inc.
Investigational New Drug Application submitted for AL044, a novel drug candidate targeting an Alzheimer’s disease risk gene Expanding clinical sites to drive additional enrollment in the INFRONT-3...
Logo with tm.png
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
June 08, 2022 07:00 ET | Alector, Inc.
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...